Next Generation Sequencing – a powerful tool for collecting genetic data!

The next-generation sequencing effort currently being executed across numerous research laboratories focuses on whole-genome sequencing with applications in diagnosing disease and assisting in treatments. Next-generation sequencing produces high-quality, sensitive, archival-accurate results in a timely manner thus enabling the researchers to conduct and compare genetic analysis. Mapping of the genetic basis of complex traits such as eye and lung disease, metabolic syndrome, and complex diseases like Alzheimer's and Huntington's disease will greatly benefit from next-generation sequencing.

Request Here Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/158

Some of the most exciting developments in next generation sequencing technology are Affinity+ and eRAXnext genomics systems that use Affinity chemistry to sequentially register and tag DNA fragments for automated tracking and analysis. Additionally, they use Affinity chemistry with Ingenuity Smart probes for multiplexed DNA analysis and tracking.

The growing need for early detection of cancer and infectious diseases is propelling growth of the next-generation sequencing market. According to the World Health Organization, approximately 13% of cancers diagnosed in 2018 globally were attributed to carcinogenic infections, including Helicobacter pylori, human papillomavirus (HPV), hepatitis B virus, hepatitis C virus, and Epstein-Barr virus. According to The Burden of Cancer Worldwide, in 2018, there were 18.1 million new cases and 9.5 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million. Moreover, the growing demand for DNA testing due to rapid advancements in whole-genome and exome sequencing procedures is further expected to augment the growth of the next-generation sequencing market.

In February 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies

In August 2020, Ancestry launches a next-generation sequencing product. The new product aims to help customers gain insights into their health and risk factors.

Download PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/158

Major Market Competitors: Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford Nanopore Technologies, and Beijing Genomics Co. Ltd.

Contact us:
Mr. Shah
Senior Client Partner – Business Development
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
sales@coherentMarketinsights.com

𝗔𝗯𝗼𝘂𝘁 𝗖𝗼𝗵𝗲𝗿𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:-
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunities.

This release was published on openPR.